Procalcitonin as a Prognostic Marker in Patients with acute ischemic stroke

Document Type : Original Research Papers

Authors

1 Professor of Neurology Faculty of Medicine - Benha University

2 Lecturer of Neurology Faculty of Medicine - Benha University

3 Department of Neuropsychiatry Medicine Faculty of Medicine-Benha University

Abstract

Background: Information about the degree of disability and death after an acute ischemic stroke remains lacking. This study's objectives were to examine the prognostic value of procalcitonin (PCT) serum levels in acute ischemic stroke (AIS). Methods: This research was a follow-up cohort study done on 70 patients referred to the neuropsychiatry department at Benha University Hospital who met the inclusion criteria for ischemic stroke. Multiple laboratory tests are performed on each patient, including (CBC, liver function tests, renal function tests, thyroid function tests, Procalcitonin (PCT) measurement within 72 hours of symptom start, CRP), CT brain (first and follow-up after 48 hs) or MRI brain with diffusion, ECG. After one month from the beginning of acute ischemic stroke, the Modified Rankin Scale (mRS) is used to assess the degree of impairment. The procalcitonin levels of acute ischemic stroke patients who died within 30 days were considerably greater than those who survived. Increasing PCT levels were shown to be linked with higher mRS scores (p0.001). A greater procalcitonin concentration was substantially related with a worse result (p 0.001, respectively). Comparing the AUCs of PCT and CRP, PCT's AUC (ability to predict bad result) was considerably superior (p=0.028). In univariable analysis, older age, hypertension, higher CRP, TLC, and PCT were related with an increased likelihood of a bad outcome. PCT is a strong predictor of poor prognosis in instances with AIS, according to the findings. PCT is an important indicator of severity and mortality after AIS.

Keywords

Main Subjects

Files

Share

How to cite

Statistics